Rani Therapeutics Holdings

General Information

We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage.

(Note: Rani Therapeutics priced its IPO on July 29, 2021, at $11 – far below its $14-to-$16 range – and sold 6.67 million shares (specifically 6,666,667 shares – the number of shares in the prospectus) to raise $73.37 million.)

Employees: 71
Founded: 2021
Contact Information
Address 2051 Ringwood Avenue San Jose, CA 95131, US
Phone Number 408-457-3700
Web Address https://www.ranitherapeutics.com
View Prospectus: Rani Therapeutics Holdings
Financial Information
Market Cap $717.8mil
Revenues $0 mil (last 12 months)
Net Income $-17.0 mil (last 12 months)
IPO Profile
Symbol RANI
Exchange NASDAQ
Shares (millions): 6.7
Price range $11.00 - $11.00
Est. $ Volume $73.4 mil
Manager / Joint Managers BofA Securities/ Stifel/ Cantor Fitzgerald/ Canaccord Genuity
CO-Managers BTIG
Expected To Trade: 7/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change